Skip to main content
≥99.0% HPLC Verified • SEPA Bank & Crypto • Min. Order €220
Metabolic Research 3 min read

AOD-9604 vs HGH Frag 176-191: C-Terminal GH Domain Structure, Disulfide Bonds, and Adipocyte Lipolysis

Compiled & reviewed by SwissLab Analytical Chemistry & QC Team — Chromatography, Mass Spectrometry & Solubility Review Desk
Editorial Standards
Analytical Summary

A comparative analytical study between AOD-9604 (Tyr-hGH 177-191) and Fragment 176-191. Disulfide cyclic constraints, beta-3 adrenergic receptor interactions, and non-diabetogenic fat oxidation assays. Fragment 176-191 reproduces the lipolytic C-terminal region of human growth hormone (hGH 176-191).

Key Research Takeaways
  • Fragment 176-191 reproduces the lipolytic C-terminal region of human growth hormone (hGH 176-191).
  • AOD-9604 is a synthetic analog (Tyr-hGH 177-191) incorporating an N-terminal tyrosine to enhance chemical stability.
  • Both peptides preserve the crucial Cys182-Cys189 intramolecular disulfide bond required for lipolytic bioactivity.
  • Neither compound activates the somatogenic GH receptor, avoiding IGF-1 elevation, insulin resistance, or glycemic perturbation.
Analytical & Handling Reference Matrix
CAS Registry Number 221231-10-3
Molecular Formula C78H123N23O23S2
Molecular Mass 1815.1 g/mol
Primary Biological Target Adipocyte Beta-3 Adrenergic Receptor & Hormone-Sensitive Lipase
Analytical Purity Standard ≥99.0% (RP-HPLC, C18, 214/220 nm)
Identity Verification ESI-MS (±0.1 Da) + Karl Fischer Moisture (<3.0%)
Lyophilized Storage -20°C desiccated, protected from UV light (24–36 months)
Reconstituted Storage 2°C–8°C refrigerated (up to 28 days in 0.9% BA BAC water)

1. Sequence Differences: AOD-9604 vs Fragment 176-191

Human Growth Hormone (191 amino acids) possesses two distinct functional domains: the somatogenic/growth-promoting domain (N-terminal) and the lipolytic domain (C-terminal residues 176–191). Synthetic Fragment 176-191 corresponds to the exact native sequence: H-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH (MW 1815.1 Da). In contrast, AOD-9604 (Advanced Obesity Drug 9604) truncates the terminal leucine and prepends an N-terminal tyrosine residue: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH (or Tyr-hGH 177-191). The addition of tyrosine optimizes peptide solid-phase synthesis yields and provides superior stability against N-terminal aminopeptidases.

2. Intramolecular Disulfide Loop Chemistry

The biological activity of both AOD-9604 and Frag 176-191 strictly depends on the formation of an intramolecular disulfide bridge between the two internal cysteine residues (Cys182 and Cys189). Linear, uncyclized variants exhibit less than 5% of the native lipolytic activity in adipocyte culture. High-resolution mass spectrometry and Ellman's reagent assays confirm 100% disulfide bridge closure in pharmaceutical-grade research batches.

3. Lipolysis and Beta-3 Adrenergic Receptor Signaling

In-vitro assays using primary white adipocytes indicate that AOD-9604 stimulates glycerol and free fatty acid release through upregulation of beta-3 adrenergic receptor (beta-3-AR) expression and hormone-sensitive lipase (HSL) phosphorylation. Crucially, competitive binding studies show that neither peptide binds to the human growth hormone receptor (hGHR). As a result, neither compound stimulates systemic IGF-1 synthesis or alters fasting blood glucose, distinguishing them from full-length recombinant hGH.

4. Analytical Testing, Reconstitution, and Storage

Both peptides are sensitive to oxidative cleavage at methionine/cysteine residues if exposed to elevated temperatures. Lyophilized vials should be stored desiccated at -20°C. Reconstitute using 1.0 mL to 2.0 mL sterile Bacteriostatic Water USP, swirling gently until optically transparent. Store reconstituted vials at 2°C to 8°C and use within 21 days for maximum experimental reproducibility.

5. Bench Preparation & Assay Reproducibility for AOD-9604 vs HGH Frag 176-191

When designing in-vitro experiments targeting Adipocyte Beta-3 Adrenergic Receptor & Hormone-Sensitive Lipase, normalize dosing across replicates by molar concentration (µM or nM) using the published molecular weight (1815.1 g/mol) and batch counterion composition rather than gross powder weight alone. Log lot numbers, diluent pH, and aliquot dates to ensure batch-to-batch reproducibility across longitudinal experiments.

Peer-Reviewed References & Analytical Standards

  1. Ng F.M. et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278. [PMID: 11146367 ↗]
  2. Heffernan M. et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology, 142(12), 5182–5189. [PMID: 11713213 ↗]

Referenced Laboratory Research Reagents

Batch-verified SwissLab catalog entries cited in this monograph

All 66 Compounds →
Laboratory Compliance & Handling Protocol

All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.

Related Research Monographs

All monographs (44)

Your Research Cart

0 items selected • Min. order €220

SEPA Bank Transfer & Crypto (BTC, ETH, USDT, USDC, SOL, XMR)
Min €220

Your cart is empty

Browse our catalog of research peptides and reagents (minimum order €220).

Browse Catalog